Medtronic's insulin pump recall gets FDA's highest-risk label

Mon, 07/15/2013 - 9:59am
Mass Device

U.S. healthcare regulators put their highest-risk Class I label on Medtronic's Paradigm insulin infusion pump recall.

Medtronic logo

The FDA put its highest-risk label, Class I, on a recall of Medtronic's (NYSE:MDT) Paradigm insulin infusion pumps, which the medtech giant had warned about earlier this year.

Medtronic Canada said last month that it received 2 reports on its Paradigm and Polyfin infusion devices, concerning the over- and under-delivery of insulin therapy.

Medtronic informed patients, healthcare providers and pharmacies in Canada of the potential problem, to explain how to avoid it, according to the Brampton Guardian.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.